🔎 Trials Near Me

Utama › Limfoma › Ohio

Kajian klinikal Limfoma di Ohio

29 kajian untuk Limfoma sedang mencari peserta di lokasi di Ohio.

Bandar di Ohio

Teks kajian rasmi (Bahasa Inggeris)

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • University Hospitals Seidman Cancer Center, Cleveland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06343311

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • University Hospitals Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07192471

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  • Cleveland Clinic, Cleveland
  • The Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07015242

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

  • University Hospitals Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 2
1 Month – 17 Years · Semua jantina · Dikemas kini 30 Sep 2026 · NCT04570423

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Mengambil pesertaFasa 1
24 Months – 18 Years · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06441331

Epco, Zanu, Ritux for R/R FL or MZL

  • The Ohio State University Wexner Medical Center, Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06563596

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  • Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT04301076

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • University of Cincinnati, Cincinnati
  • The Cleveland Clinic Foundation, Cleveland
  • The Ohio State University, Columbus
  • dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07221500

Collection of Tissue Samples for Cancer Research

  • Ohio State University, Columbus
Mengambil pesertaKajian pemerhatian
2 Months · Semua jantina · Dikemas kini 16 Sep 2026 · NCT00900198

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Mengambil pesertaFasa 1/2
12 Months – 21 Years · Semua jantina · Dikemas kini 11 Sep 2026 · NCT04870944

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Cleveland
Mengambil pesertaFasa 3
Umur 18 hingga 18 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07509151

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
  • Cleveland Clinic, Cleveland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

  • Cleveland Clinic, Cleveland
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06678659

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Cincinnatti Medical Center, Cincinnatti
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06528301

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Oncology Hematology Care Clinical Trials, Cincinnati
  • University of Cincinnati, Cincinnati
  • Cleveland Clinical Taussig Cancer Center, Cleveland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • The Ohio State University Wexner Medical Center James Cancer, Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

  • University Hospitals Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jul 2026 · NCT07465835

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Columbus
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Jun 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

  • The Ohio State University, Columbus
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Apr 2026 · NCT06801002

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Cleveland Clinic, Cleveland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT07356245

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Gabrail Cancer Center Research,, Canton
Mengambil pesertaFasa 1/2
Umur 12 hingga 95 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04329728

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Cleveland Clinic, Cleveland
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Nov 2025 · NCT06916767

HPC Offered for PRESERVE Expansion

  • The Ohio State University Medical Center, Columbus
Mengambil pesertaKajian pemerhatian
Umur 12 hingga 80 · Semua jantina · Dikemas kini 28 Ogo 2025 · NCT07145411

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.